Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2 Pt 1
|
pubmed:dateCreated |
1988-9-2
|
pubmed:abstractText |
Pirmenol is an investigational type 1A antiarrhythmic drug the long-term efficacy of which has not been fully determined. Therefore the long-term efficacy of oral pirmenol in suppressing ventricular premature depolarizations (VPDs) was assessed in an open-label, dose-titration study. Twelve patients (eight men and four women; mean age 57 +/- 12 years) were treated for 24 to 36 months (mean 33 +/- 4). Seven had structural heart disease (three valvular heart disease, two ischemic heart disease, and two hypertensive heart disease) and five did not. The mean left ventricular ejection fraction was 0.63 +/- 0.13. Exclusion criteria included less than 30 VPDs/hr, greater than 15 beats of ventricular tachycardia (VT), or prior failure of more than two antiarrhythmic drugs. Drug efficacy was assessed by 24-hour ambulatory ECG monitoring performed every 3 months during the first year, every 4 months during the second year, and at 6-month intervals during the third year. The mean hourly frequency of VPDs during the placebo phase was 732 +/- 608. Seven patients (58%) were treated successfully with effective (greater than 75%) long-term suppression of VPDs. Two patients (17%) had a partial response with effective suppression of VPDs for the first 16 months and 5 months of treatment, respectively. Three patients failed to show consistent suppression of VPDs while receiving pirmenol. The daily dose of pirmenol ranged from 200 to 500 mg (mean 317 +/- 94 mg at the beginning of the study and 375 +/- 97 mg at the end). No proarrhythmic effects were identified during long-term treatment, and none of the patients withdrew from the study prematurely.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0002-8703
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
116
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
379-84
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2456681-Administration, Oral,
pubmed-meshheading:2456681-Adult,
pubmed-meshheading:2456681-Aged,
pubmed-meshheading:2456681-Anti-Arrhythmia Agents,
pubmed-meshheading:2456681-Cardiac Complexes, Premature,
pubmed-meshheading:2456681-Clinical Trials as Topic,
pubmed-meshheading:2456681-Double-Blind Method,
pubmed-meshheading:2456681-Electrocardiography,
pubmed-meshheading:2456681-Female,
pubmed-meshheading:2456681-Heart Ventricles,
pubmed-meshheading:2456681-Humans,
pubmed-meshheading:2456681-Male,
pubmed-meshheading:2456681-Middle Aged,
pubmed-meshheading:2456681-Piperidines,
pubmed-meshheading:2456681-Random Allocation,
pubmed-meshheading:2456681-Time Factors
|
pubmed:year |
1988
|
pubmed:articleTitle |
Long-term efficacy of oral pirmenol in suppressing ventricular premature depolarizations.
|
pubmed:affiliation |
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0022.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|